Virtual Library

Start Your Search

Jianhui Huang



Author of

  • +

    P1.03 - Biology (Not CME Accredited Session) (ID 935)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.03-02 - Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer (ID 11107)

      16:45 - 18:00  |  Presenting Author(s): Jianhui Huang

      • Abstract
      • Slides

      Background

      Mothers against decapentaplegic homolog 4 (SMAD4) is an important protein in cancers. It plays pivotal roles in cellular pathways, including apoptosis. While the genetic locus of SMAD4 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring SMAD4 mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A total of 451 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of SMAD4 mutation and other genes were detected by next generation sequencing.

      4c3880bb027f159e801041b1021e88e8 Result

      SMAD4 gene mutation rate was 1.77% (8/451) in non-small cell lung cancer, including R361H (3 patients), C324Y (1 patient), E526Q (1 patient), Q289* (1 patient), D493G (1 patient) and P522R (1 patient), and median overall survival (OS) for these patients was 13.0 months. Among them, all patients were SMAD4 gene with co-occurring mutation. Briefly, patients with (n=2) or without (n=6) co-occurring EGFR mutations had a median OS of 10.0 months and 15.0 months respectively (P=0.18); patients with (n=5) or without (n=3) co-occurring TP53 mutations had a median OS of 10.0 months and 19.5 months respectively (P=0.18); patients with (n=3) or without (n=5) co-occurring KRAS mutations had a median OS of 10.0 months and 15.0 months respectively (P=0.30); patients with (n=3) or without (n=5) co-occurring CDKN2A mutations had a median OS of 10.0 months and 15.0 months respectively (P=0.22).

      8eea62084ca7e541d918e823422bd82e Conclusion

      There are some significant difference of clinical features in SMAD4 gene mutations with smoking advance NSCLC. SMAD4 gene inactivation is associated with poorer prognosis in patients with NSCLC.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.